Germline CDKN2A mutations in Brazilian patients of hereditary cutaneous melanoma

Familial Cancer

Volumn 13, Issue 4, 2014, Pages 645-649

  de Ávila, Alexandre Leon Ribeiro ^a   Krepischi, Ana Cristina Victorino ^a,b   Moredo, Luciana Facure ^a   Aguiar, Talita Ferreira Marques ^a   da Silva, Felipe Carneiro ^a   de Sá, Bianca Costa Soares ^a   de Nóbrega, Amanda França ^a   Achatz, Maria Isabel Waddington ^a,b   Duprat, João Pedreira ^a   Landman, Gilles ^c   Carraro, Dirce Maria ^a,b  

^a A C CAMARGO CANCER CENTER   (Brazil)

^b National Institute of Science and Technology in Oncogenomics   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

CDKN2A; Familial cutaneous melanoma; Genetic screening; Genomic rearrangements; Melanoma susceptibility; Multiple melanomas

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ADULT; ARTICLE; BRAZILIAN; CANCER SCREENING; CANCER SUSCEPTIBILITY; CUTANEOUS MELANOMA; DNA POLYMORPHISM; FAMILIAL CANCER; FEMALE; GENE MUTATION; GENETIC SCREENING; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; MUTATION RATE; PANCREAS CANCER; POINT MUTATION; PRIORITY JOURNAL; SOUTH AND CENTRAL AMERICA; BRAZIL; GENETIC PREDISPOSITION; GENETICS; GERMLINE MUTATION; MELANOMA; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; YOUNG ADULT;

ADULT; BRAZIL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENES, P16; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MALE; MELANOMA; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 84920875735     PISSN: 13899600     EISSN: 15737292     Source Type: Journal    
DOI: 10.1007/s10689-014-9736-1     Document Type: Article

References (29)

1. Tsao H, Atkins MB, Sober AJ (2004) Management of cutaneous melanoma. N Engl J Med 351:998–1012
2. Agarwala SS (2009) Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther 9:587–595
3. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507–2516
4. Kahn HJ, Hanna WM, Chapman JA, Trudeau ME, Lickley HL, Mobbs BG et al (2006) Biological significance of occult micrometastases in histologically negative axillary lymph nodes in breast cancer patients using the recent American Joint Committee on Cancer breast cancer staging system. Breast J 12:294–301
5. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723
6. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Zanetti R, Masini C et al (2005) Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer 41:2040–2059
7. Leachman SA, Carucci J, Kohlmann W, Banks KC, Asgari MM, Bergman W et al (2009) Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol 61(677):e1–e14
8. Kannengiesser C, Avril MF, Spatz A, Laud K, Lenoir GM, Bressac-de-Paillerets B (2003) CDKN2A as a uveal and cutaneous melanoma susceptibility gene. Genes Chromosomes Cancer 38:265–268
9. Tsao H, Chin L, Garraway LA, Fisher DE (2012) Melanoma: from mutations to medicine. Genes Dev 26:1131–1155
10. Puntervoll HE, Yang XR, Vetti HH, Bachmann IM, Avril MF, Benfodda M et al (2013) Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. J Med Genet 50:264–270
11. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A et al (2013) TERT promoter mutations in familial and sporadic melanoma. Science 339:959–961
12. Ghiorzo P, Bonelli L, Pastorino L, Bruno W, Barile M, Andreotti V et al (2012) MC1R variation and melanoma risk in relation to host/clinical and environmental factors in CDKN2A positive and negative melanoma patients. Exp Dermatol 21:718–720
13. Yokoyama S, Woods SL, Boyle GM, Aoude LG, MacGregor S, Zismann V et al (2011) A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 480:99–103
14. Goldstein AM, Chan M, Harland M, Hayward NK, Demenais F, Bishop DT et al (2007) Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet 44:99–106
15. Larre Borges A, Borges AL, Cuéllar F, Puig-Butillé JA, Scarone M, Delgado L et al (2009) CDKN2A mutations in melanoma families from Uruguay. Br J Dermatol 161:536–541
16. Grazziotin TC, Rey MC, Bica CG, Pinto LA, Bonamigo RR, Puig-Butille JA et al (2013) Genetic variations of patients with familial or multiple melanoma in Southern Brazil. J Eur Acad Dermatol Venereol 27:e179–e185
17. Bakos RM, Besch R, Zoratto GG, Godinho JM, Mazzotti NG, Ruzicka T et al (2011) The CDKN2A p.A148T variant is associated with cutaneous melanoma in Southern Brazil. Exp Dermatol 20(11):890–893
18. Ashton-Prolla P, Bakos L, Junqueira G Jr, Giugliani R, Azevedo SJ, Hogg D (2008) Clinical and molecular characterization of patients at risk for hereditary melanoma in southern Brazil. J Invest Dermatol 128(2):421–425
19. Huber J, Ramos ES (2006) The P48T germline mutation and polymorphism in the CDKN2A gene of patients with melanoma. Braz J Med Biol Res 39(2):237–241
20. Silva AG, Ewald IP, Sapienza M, Pinheiro M, Peixoto A, de Nóbrega AF et al (2012) Li-Fraumeni-like syndrome associated with a large BRCA1 intragenic deletion. BMC Cancer 12:237
21. Silva FC, Lisboa BC, Figueiredo MC, Torrezan GT, Santos EM, Krepischi AC et al (2014) Hereditary breast and ovarian cancer: assessment of point mutations and copy number variations in Brazilian patients. BMC Med Genet 15(1):55
22. Torrezan GT, da Silva FC, Krepischi AC, Santos E, de O Ferreira F, Rossi BM et al (2011) Breakpoint characterization of a novel large intragenic deletion of MUTYH detected in a MAP patient: case report. BMC Med Genet 12:128
23. Torrezan GT, Carneiro da Silva FC, Krepischi AC, Monteiro Dos Santos EM, Rossi BM, Carraro DM (2012) A novel SYBR-based duplex qPCR for the detection of gene dosage: detection of an APC large deletion in a familial adenomatous polyposis patient with an unusual phenotype. BMC Med Genet 13:55
24. Krepischi AC, Pearson PL, Rosenberg C (2012) Germline copy number variations and cancer predisposition. Future Oncol 8:441–450
25. Campos AH, Silva AA, Mota LD, Olivieri ER, Prescinoti VC, Patrão D et al (2012) The value of a tumor bank in the development of cancer research in Brazil: 13 years of experience at the AC Camargo hospital. Biopreserv Biobank 10(2):168–173
26. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G (2002) Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 30:e57
27. Liu L, Dilworth D, Gao L, Monzon J, Summers A, Lassam N (1999) Mutation of the CDKN2A 5′-UTR creates an aberrant initiation codon and predisposes to melanoma. Nat Genet 21:128–132
28. Harland M, Mistry S, Bishop DT, Bishop JA (2001) A deep intronic mutation in CDKN2A is associated with disease in a subset of melanoma pedigrees. Hum Mol Genet 10(23):2679–2686
29. Helsing P, Nymoen DA, Ariansen S, Steine SJ, Maehle L, Aamdal S et al (2008) Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas. Genes Chromosomes Cancer 47(2):175–184